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(57) ABSTRACT 
The present invention generally relates to stimuli-responsive 
drug carriers and methods for making. More specifically, the 
present invention relates to stimuli-responsive lidded par 
ticles that respond to a physiological stimulus and dissolve at 
a target site inside the body thereby releasing therapeutic 
agents. The present invention further relates to Solid, drug 
loaded particles that are made from biodegradable polymers. 
The present invention further relates to methods for fabricat 
ing lidded particles and particles for drug delivery. 
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FIGURE 9 
Wafer calculations: 
Diameter of wafer - 4 - 101,600 m = 101,600,000nm 
o Radius of water = 2 = 50,800um - 50,800,000mm 
Area of wafer = "r = 8.107 x o sum = 8.107 x 10' nm 
50 x50m container calculations: 
8 Area of container size t / spacing - 
54 um x 54am =2916pm 
8 Number of containers = (8.107 X 10 
um), 2916 m = 2.78 x 10' 
300 x 300 nm container calculations: 
e Area of container size + A Spacing - 
600nm x 600nm =360000nm' 
• Number of containers = (8.107 x 10' 
nm), 360000nm’= 2.25 x 10" 600 
600 
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METHODS FOR FABRICATING NANO AND 
MCROPARTICLES FOR DRUG DELVERY 
PRIORITY CLAIM 
This application claims priority to U.S. Provisional Appli 
cations Nos. 60/678,639 filed May 6, 2005 and 60/719,844 
filed Sep. 23, 2005, the contents of which are incorporated in 
their entireties herein. 
BACKGROUND OF THE INVENTION 
Therapeutic and diagnostic applications of nanofabrica 
tion technology are gaining increasing interest. Over the past 
several decades almost all efforts in controlled release drug 
delivery has been focused on polymer-based, diffusion/deg 
radation-controlled delivery strategies. Current “controlled 
release' drug delivery systems are based primarily on par 
ticles or matrices of various polymers and lipids where the 
release of the therapeutic agent is controlled primarily by 
diffusion and hydrolytic degradation. Although progress has 
been made and several new products are coming in the market 
that can significantly enhance patient compliance, reduce 
side effects, and improve the quality of life, there remain 
several limitations of these approaches. 
First, despite the development of sophisticated and sensi 
tive assays to study drug release and polymer degradation in 
vitro, little correlation exists between in vitro observations 
and in vivo performance of diffusion/degradation controlled 
devices. The effects of tissue environments in vivo, especially 
tissue pH, enzymes, salt concentrations, and the rarity with 
which perfect sink conditions are met, makes most prediction 
of drug diffusion/release inherently inaccurate. 
Second, delivery systems that rely on particle-based strat 
egies, e.g., micro and nanoparticles for tissue targeted deliv 
ery, suffer from the limitation that the bottom-up synthesis 
processes produce a large polydisperse population of par 
ticles whose physico-chemcial characteristics, drug release 
profiles, degradation kinetics, and material properties 
become hard to evaluate and reproduce, especially at phar 
maceutical scales. 
Third, the lack of a stimuli-responsive release mechanism 
results in the release of the drug in a somewhat uncontrolled 
manner, which often results in Systemic side effects. 
Fourth, particle-based drug carriers rely on emulsion or 
micelle formation for synthesis and drug loading, thereby 
achieving only limited and often poor encapsulation effi 
ciency. This limitation becomes particularly critical of highly 
expensive and difficult to synthesize drugs, leading to limited 
application and high cost. Strategies to enhance drug entrap 
ment within carriers would therefore be highly beneficial. 
Fifth, combining multiple functionalities (i.e., both target 
ing as well as stimuli-sensitive properties), in a controlled and 
reproducible manner is significantly difficult in self-as 
sembled carrier systems. Polymer-based pro-drugs offer the 
closest design to Such combinatorial approach (Ulbrich et al., 
J. Control Release 2000, 64:63-79; Peterson et al., Adv. Exp. 
Med. Biol. 2003, 519:101-23; Ulbrich et al., J. Control 
Release 2003, 87:33-47; Ulbrich and Subr, Adv. Drug Deliv. 
Rev. 2004, 56:023-50; Rihova et al., J. Control Release 2000, 
64:41-61; Kovar et al., J. Control Release 2004, 99:301-14: 
Kopecek et al., Eur: J. Pharm. Biopharm. 2000, 50:61-81). 
However, such designs do not allow for simultaneous delivery 
of multiple agents (drugs, contrast agents etc.) and are yet to 
have demonstrated conclusive clinical efficacy. Newer 
approaches in delivery of therapeutics are therefore urgently 
needed. 
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A key issue in drug delivery is disease-responsive release. 
Despite current efforts to target drug nanoparticles and lipo 
Somal drug carriers to diseased cells in Vivo (Kreuter, J. 
Nanosci. Nanotechnol. 2004, 4:484-8; Parket al., Adv. Phar 
macol. 1997, 40:399-435; Park et al., Semin. Oncol. 2004, 
31: 196-205; Noble et al., Expert Opin. Ther. Targets 2004, 
8:335-53), it is inevitable that during transport to target cells 
and the extracellular residence time, significant amounts of 
toxic drugs will diffuse to normal tissues. A combination of 
both cellular targeting and disease-specific, stimuli respon 
sive delivery would provide a significantly improved design. 
Although several concepts have been proposed to address the 
issues of stimuli responsiveness (Peppas et al., Eur: J. Pharm. 
Biopharm. 2000, 50:27-46; Miyata et al., Adv. Drug Deliv. 
Rev. 2002, 54:79-98; Qiu and Park, Adv. Drug Deliv Rev. 
2001, 53:321-39) and tissue targeting (Park et al., 1997, 
supra; Parket al., 2004, supra; Ulbrich et al., 2000, supra; Lu 
et al., J. Control Release 2002.78:165-73), the inherent com 
plexity of bottom-up (i.e. self-assembly) synthetic 
approaches (e.g., emulsions or micelles) makes it difficult to 
incorporate both these functionalities in a single delivery 
platform. A top-down nanomachining approach that would 
ensure triggered bolus release of drugs, primarily in response 
to a specific stimulus, from a highly monodisperse population 
of carriers could provide significantly improved alternatives 
to currently available diffusion/hydrolysis controlled sys 
temS. 
Current MEMS-Based Drug Delivery Devices 
Micro and nano-electromechanical systems have tradition 
ally been used for the integrated circuit industry. Several 
groups have recently reported micro-electromechanical sys 
tems (MEMS)-based drug delivery devices (Desai et al., Bio 
technol. Bioeng. 1998, 57:118-20; Richards Grayson et al., 
Nat. Mater. 2003, 2:767-72; Richards Grayson et al., J. 
Biomed. Mater. Res. A 2004, 69A: 502-12; Tao et al., J. 
Control Release 2003a, 88:215-28; Tao et al., J. Biomed. 
Mater Res. A 2003b, 67:369-75; Santini et al., Nature 1999, 
397:335-8: Santini et al., Angew. Chem. Int. Ed. Engl. 2000, 
39:2396-2407). 
Desai et al. (1998, supra; 2001, supra) reported a micro 
machined nanoporous immunoisolation capsule, 4 mmx4 
mmx110 um in size, for encapsulation of islet cells and use in 
insulin delivery for diabetic patients. More recently, Langer 
and colleagues developed an implantable, controlled release 
microchip, 17 mmx17 mmx310 um in size, with 34 drug 
reservoirs that can be used to deliver multiple drugs or doses 
at pre-designed time intervals (Santini et al., 1999, supra; 
Santini et al., 2000, supra). The reservoirs were sealed with a 
thin gold membrane that can be dissolved using an external 
electrical trigger. Subsequently the same group reported a 
degradable design of the multi-pulse microchip device using 
poly(L-lactic acid) (Richards Grayson et al., 2003, supra; 
Richards Grayson et al., 2004, supra). Micromachined par 
ticulate type drug delivery devices have been reported by 
Desai and colleagues (Tao et al., 2003a, Supra; Tao et al., 
2003b, supra: Ahmed et al., J. Control Release 2002, 81:291 
306; Tao and Desai, Adv. Drug Deliv Rev. 2003, 55:315-28). 
They developed bioadhesive microdevices fabricated either 
from silicon or poly(methyl methacrylate) (PMMA) for 
applications in oral drug delivery. The silicon devices were 50 
um with 25um reservoirs, and the PMMA microdevices were 
150 um with 80 um reservoirs. Both were fabricated using 
standard photolithography processes. It was also shown that 
Surface modification of the devices to attach targeting ligands 
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(e.g., lectins) was achievable through avidin-biotin chemistry 
(Tao et al., 2003a, supra; Amed et al., 2002, supra). 
Despite these efforts, major limitations in the drug delivery 
devices remain. First, these devices are too large (>50 um) to 
be injected in blood. Second, they do not have any sensing 
mechanism to be physiologically responsive. The concept of 
intravenously injectable (i.e., nanosize), stimuli responsive 
devices of precise size and shape, capable of intracellular or 
intratumoral drug delivery has not been explored. For a nano 
fabricated device to be delivered systemically it must be at 
least less than 5 um (preferably less than 1 um) and to be 
efficiently internalized by non-phagocytic cells (e.g., tumor 
cells) it should be less than 300 nm in size. Significant tech 
nological challenges exist in fabricating Such small carriers 
along with disease-responsive features using a purely top 
down approach. 
Nanoimprint Lithography 
Several novel nanofabrication concepts (Colburn et al., 
Proc. SPIE, Mar. 15-17, 1999 3676, 379-389, 1999; Hooper 
et al., in 2003 Nanotechnology Conference and Trade Show— 
Nanotech 2003, Feb. 23-27, 2003, 3:47-50, Computational 
Publications, Cambridge, Mass., 2003; Johnson et al., in 
Proc. 28th Intl Conf. MNE, Sep. 16-19, 2002, 67-68:221-228, 
Elsevier, Lugano, Switzerland, 2003; Johnson et al., in 
Emerging Lithography Technologies VII, Feb. 25-27, 2003. 
5037 1:197-202, Int. Soc. Optical Eng., Santa Clara, Calif., 
2003; Resnicket al., Microelec. Eng. 2003, 69:412-419; Choi 
et al., in Emerging Lithographic Technologies V. Feb. 27-Mar. 
1, 2001, 4343:436-442, Soc. Photo-Optical Instrumen. Eng., 
Santa Clara, Calif., 2001) are available, such as step-and-flash 
imprint lithography (S-FILTM) (Bailey et al., in Micro and 
Nano Engineering 2001, Sep. 16-19, 2001, 61-62:461–467, 
Elsevier Science B.V., Grenoble, 2002) and thermal nanoim 
print lithography (ThNIL) (Chou et al., Science 1996, 272: 
85-87). 
S-FILTM is essentially an improved version of a micro 
molding method, in which the topography of a template 
defines the patterns imprinted on a Substrate. It is based on a 
very low-viscosity (approximately 2-3 cps) liquid imprinting 
monomer that is UV-curable. This leads to a very low pressure 
(<1 psi) and a room-temperature process particularly suitable 
for high-resolution, layer-to-layer alignment. It avoids distor 
tion in the imprinted features, a common problem in tradi 
tional high pressure (e.g., >10 MPa)/high temperature (e.g., 
>glass transition temperature of the polymer film) micro 
molding processes. The low viscosity allows for sub-20 nm 
resolution and in situ, lubricated alignment corrections with 
sub-100 nm alignment accuracy. Further, the lubricated con 
tact, low pressure, and room temperature minimizes template 
damage, and the step and repeat process allows for a small and 
reusable template that can handle 2-8 inch wafers. 
One attractive feature of the S-FILTM process is its ability to 
print three-dimensional nanostructures. The Smallest line 
widths printed to date are 20 nm, since this is the minnimum 
trench width that has been fabricate on the imprint template. 
Smaller features such as sub-10 nm stitching errors of the 
electron beam lithography (EBL) tools, which were used to 
make the templates, have been reproduced with high fidelitiy. 
Three-dimensional structures can be replicated by the 
S-FILTM process and patterns can be imprinted on top of 
existing topography by using an appropriate planarization 
material. The ability for 3D patterning is particularly useful 
for fabricating nanocontainers for drug delivery. While the 
nanoimprinting process is sensitive to particles and is done in 
a very clean environment, S-FILTM has shown a remarkable 
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self-cleaning capability: if a contaminated template is used to 
imprint, after a few imprints, a clean template and imprinted 
structures can be obtained. 
A different nano-imprint process is thermal nanoimprint 
lithography (ThNIL) in which the device material (e.g., poly 
mer) is heated above its glass transition temperature and 
imprinted using a template similar to the S-FILTM process. 
The material is then cooled back to ensure a permanently 
imprinted topography. FIG. 1 shows scanning electron micro 
graph (SEM) images of PMMA and benzyclucobutene 
(BCB) lines patterned using a ThNIL method. 
SUMMARY OF THE INVENTION 
The present invention relates to stimuli-responsive drug 
carriers and methods for making. In a particular embodiment 
of the present invention, the stimuli-responsive drug carriers 
are nano- and microparticles with an imprinted “lid' (referred 
to herein as "lidded particles') that effectively “sense a 
physiological stimulus (e.g., disease-specific conditions) and 
consequently dissolve at a target site inside the body thereby 
releasing therapeutic agents. 
The present invention further provides for lidded particles, 
wherein the lidded particles are from 200 mn to 1000 nm in 
size. In a particular embodiment, the lidded particles of the 
present invention are from 200 nm to 800 nm in size. In a 
particular embodiment, the lidded particles are from 200 nm 
to 400 nm in size. 
A further embodiment provides for stimuli-responsive lid 
ded particles that can be targeted for intracellular delivery in 
tumor cells. 
The present invention further provides for stimuli-respon 
sive lidded particles, wherein the stimuli responded to is a 
disease condition. In a further embodiment, the disease con 
dition is a tumor. 
In a particular embodiment, the stimuli-responsive lidded 
particles are made of a biodegradable polymer Such as 
PMMA. 
The present invention further provides for lidded particles, 
wherein the lid is made of an enzyme-degradable, photo 
crosslinkable polymer membrane. A particular embodiment 
provides that the enzyme-degradable lid degrades specifi 
cally in the presence of cathepsins. In a specific embodiment, 
the enzyme-degradable photo-crosslinkable polymer mem 
brane of the lid is an acrylated PEG-peptide-PEG triblock 
copolymer membrane. 
The present invention further provides drug-loaded poly 
mer nano- and microparticles (referred to herein as “par 
ticles”) that are entirely fabricated using stimuli-responsive 
or biodegradable polymers. The present invention further 
provides for drug-loaded particles, wherein the particles are 
from 50 mn to 1000 nm in size. In a particular embodiment, 
the particles of the present invention are from 50 nm to 400 
nm in size. In a preferred embodiment, the particles are from 
50 nm to 300 nm in size. 
The invention further provides that the particles are made 
from biodegradable polymers, such as the biodegradable 
polymer PMMA. In alternative embodiments, the biodegrad 
able polymer of the particles is PLGA. 
In specific embodiments, the particles are disease-condi 
tion responsive, wherein the particle is degradable by an 
enzyme specifically associated or expressed in a disease state. 
The present invention further provides a method for mak 
ing a particle comprising providing an imprint template and a 
patternable biodegradable polymer, and conducting an 
imprint process on the polymer, thereby forming a particle. 
The present invention further provides for a method of mak 
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ing a particle, wherein the imprint template is formed using 
e-beam lithography, reactive ion etching, or both. 
In a specific embodiment, the method for making a particle 
further provides that the polymer comprises a compound 
comprising polymethyl-methacrylate, polyethylene func 
tionalized peptide or a combination thereof. In a particular 
embodiment, the method of making a particle further pro 
vides an imprint process comprising a technique comprising 
a thermal nanoimprint process, a S-FIL process, UV lithog 
raphy or combinations thereof. 
The present invention further relates to methods for mak 
ing lidded particles, comprising operatively attaching a 
formed lid to a formed particle having a size less than about 50 
nm. The invention further provides for a lidded particle 
formed using e-beam lithography and reactive ion etching. 
In a specific embodiment, the method of making a lidded 
particles comprises pressing an imprint template into a UV 
curable monomer for S-FILTM: UV curing the monomer to 
form a cured monomer wafer, separating the imprint template 
from the cured monomer wafer, cleaning residual monomers 
from the cured monomer wafer; coating the cured monomer 
wafer with a therapeutic agent; removing excess therapeutic 
agent from the cured monomer wafer, pressing a second 
imprint template on the wafer coated with PEG-GFLGK 
hydrogel; UV curing the hydrogel; cleaning the cured hydro 
gel after the template is removed. 
Both the lidded particles and particles are designed to be 
injected either systemically or locally for targeted delivery to 
diseased cells and would release the desired drug exclusively 
in the presence of specific physiological signals, e.g., tumor 
associated enzymes. 
BRIEF DESCRIPTION OF THE FIGURES 
A more complete understanding of this disclosure may be 
acquired by referring to the following description taken in 
combination with the accompanying figures in which: 
FIG. 1 is a SEM image of nano-imprint lines (3A) 20-nm 
wide PMMA lines, (3B) 50-nm-wide PMMA lines, (3C) 
BCB lines with different line width as small as 10 nm. 
FIG. 2 is schematic diagram of a disease-responsive drug 
delivery nanocontainer with potential targeting and simulta 
neous imaging capabilities. 
FIG. 3 is a graph showing a MALDI-TOF mass spectrom 
etry analysis of peptide conjugation to PEG-acrylate mol 
ecules. Peaks are at 3707 and 7256 m/z. 
FIG. 4 is a schematic of the thermal and S-FILTM-based 
nanoimprint fabrication process of PMMA lidded particles 
with PEG-peptide-PEG lids: (4A) press an imprint template 
into the UV curable monomer for S-FILTM; (4B) UV curing 
the monomer; (4C) after the template is separated from the 
wafer; (4D) after a timed O. plasma cleaning of monomer 
residuals; (4E) spin on a therapeutic agent solution and dry; 
(4F) rinse and remove therapeutic agent particles from the 
SiO surface; (4G) press the second imprint template on the 
wafer coated with PEG-GFLGKhydrogel; (4H) UV curing of 
the hydrogel; (4I) after the template is removed and a short O. 
plasma cleaning. The diagram also indicates a process 
involved for drug loading. 
FIG.5is a SEM image of 200 nm (5A,5E),400 nm (5B,5F, 
5C) and 800 nm (5D) particles features fabricated using the 
proposed EBL, RIE and ThNIL techniques. FIGS.5A and 5B 
illustrate the EBL process for creating precise templates for 
nanoimprinting. FIGS. 5C and 5D show the results obtained 
with RIE. FIGS. 5E and 5F show the thermal imprinting 
process using PMMA. As shown, precise 200 nm and 400 nm 
particle-lid structures can be generated using this process. 
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FIG. 6 is a schematic diagram of the fabrication process of 
Solid nanoparticles of various sizes and shapes using thermal 
nanoimprinting: (6A) spin on release layer onto imprint tem 
plate; (6B) spin on polymer, (6C) apply pressure and heat; 
(6D) after the template is separated from the wafer, (6E) after 
a timed oxygen plasma cleaning of monomer residual. 
FIG. 7 shows SEM images of e-beam imprint template for 
nanofabricated Solid particles. 
FIG. 8 shows SEM images imprinted PEGDA solid nano 
particles using the template from FIG. 7 and the S-FIL pro 
cess. (8A, top left) 200 nm pentagons; (8B, top right) 200 nm 
squares; (8C, bottom left) 200 nm triangles; (8D, bottom 
right) 100 nm squares. 
FIG. 9 is a diagram showing calculations of particle num 
bers from a single silicon wafer. 
DETAILED DESCRIPTION 
The present invention generally relates to stimuli-respon 
sive drug delivery particles, and methods for making Such 
particles. The particles of the present invention comprise two 
types—"lidded particles” and “particles.” 
Lidded Particles 
According to the present invention, "lidded particles' are 
biocompatible nano- or microparticles fabricated by nano- or 
microfabrication techniques that further comprise an enzy 
matically degradable lid that can “sense' a physiological 
stimulus and dissolve at a target site inside the body, thereby 
releasing therapeutic agents (FIG. 2). 
In a specific embodiment, the present invention relates to 
injectable lidded particles (200-800 nm overall dimension 
with <50 nm features) with a nanoimprinted “lid’ that can 
effectively “sense' a physiological stimulus (disease-spe 
cific) and consequently release therapeutic agents at a target 
site inside the body. In particular embodiments, the nanocon 
tainers are on the order of 200-800 nm overall dimension with 
less than 50 nm features. In a specific embodiment, the lidded 
particles are injected systemically. In an alternate embodi 
ment, the nanocontainers are injected locally for targeted 
delivery to diseased cells. In a specific embodiment, the 
locally targeted lidded particles would release the desired 
drug exclusively in the presence of specific physiological 
signals, e.g., tumor-associated enzymes. 
In specific embodiments, the lidded particles of the present 
invention further comprise a payload, Such as a therapeutic 
agent. The present invention also provides methods of mak 
ing Such containers. The lidded particles of the present inven 
tion may be capable of containing a payload for release at a 
desired time or location, or both. Accordingly, the lidded 
particles of the present invention may be suitable for use in a 
Subject, for example, an animal Subject (e.g., a human), and 
the lidded particles of the present invention may be used in 
methods for treating a Subject. 
Particles 
According to the present invention, “particles' are biocom 
patible nano-or microparticles fabricated by nano- or micro 
fabrication techniques. In the context of this disclosure, the 
term “nanoparticles, microparticles' and “particles' may be 
used interchangeably. 
In specific embodiments, the particles of the present inven 
tion further comprise a payload, Such as a therapeutic agent. 
The present invention also provides methods of making Such 
particles. The particles of the present invention may be 
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capable of containing a payload for release at a desired time. 
Accordingly, the particles of the present invention may be 
Suitable for use in a subject, for example, an animal Subject 
(e.g., a human), and the particles of the present invention may 
be used in methods for treating a subject. 
Targeting Devices (Lidded Particles and Particles) 
In certain embodiments, the devices (lidded particles and 
particles) of the present invention may be capable of targeting 
specific cells or tissues. Such as diseased cells or tissues. For 
example, ligands and biomolecules specific for a target cells 
may be chemically conjugated to the device Surface using 
standard techniques. 
In some embodiments, the lidded particles and particles of 
the present invention may be suitable as a stimuli-responsive 
drug release device. The lidded particles and particles of this 
embodiment comprise a stimuli-sensitive release mecha 
nism, nanofabricated into the container or particle structure. 
Such mechanisms may be used, among other things, to 
enhance delivery of a therapeutic agent by allowing releasef 
administration of the therapeutic agent in response to a Sub 
jects therapeutic needs. In many instances, this could reduce 
systemic side effects, among other things, by targeting release 
and administration of the therapeutic agent to the target tissue 
and cellular compartments. 
The lidded particles and particles of the present invention 
also may be used for simultaneous noninvasive monitoring of 
a therapeutic agent and the container and particle, following 
administration. For example, imaging contrast agents are 
incorporated along with the therapeutic drugs. Examples of 
imaging contrast agents include quantum dots, gold nanopar 
ticles or Gadalonium-diethylenetriaminepentaacetate (Gd 
DTPA) (for use in magnetic resonance imaging (MRI)) and 
simultaneously image the particles in the body as they deliver 
and/or releases the drugs. Among other things, this allows the 
evaluation of the efficacy of the device, for example, in reach 
ing the target cells, intracellular uptake, and Subsequent thera 
peutic agent release. In certain embodiments, Gadalonium 
may be chemically conjugated to the device surface or loaded 
along with atherapeutic agent. Next, in vivo transport may be 
monitored using MRI techniques. 
The lidded particles and particles may be formed from a 
MEMS or NEMS-based device. In general, the lidded par 
ticles and particles of the present invention have a size Suit 
able for a desired application. For a MEMs-based lidded 
particle or particle of the present invention to be injectable, it 
must be less than about 5um in size. Similarly, MEMs-based 
lidded particles or particles of the present invention to be 
taken up by a non-phagocytic cell, must be at least less than 
500 nm in size. Accordingly, micro-sized lidded particles and 
particles may beformed having a size in the range of about 0.5 
um to about 50 Lum. Nano-sized lidded particles and particles 
may be formed having sizes less than about 500 nm, among 
other things, for applications in which injection into a subject 
is desired. 
The lidded particles and particles of the present invention 
may be formed using any suitable fabrication technique. For 
example, lidded particles and particles may be formed using 
nano-imprint lithography techniques. In some embodiments, 
the present invention uses a top-down micro- or nanofabrica 
tion technology coupled with an enzymatically degradable 
polymer to form injectable micro- and nanocontainers (the 
lidded particles). In specific embodiments, particles and lid 
ded particles may be formed using S-FIL techniques. These 
fabrication techniques, among other things, may allow for 
exquisite control over the size and shape of the particles and 
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lidded particles and would produce highly monodisperse 
population of particles. This may allow precise control of 
drug release kinetics and tissue targeting with little or no 
batch-to-batch variation in properties. 
The lidded particles and particles of the present invention 
may be formed from any biocompatible material, for 
example, PMMA, silicon and silicon derivatives. In some 
embodiments, the lidded particles and particles may be 
formed of a biodegradable material, for example, a biode 
gradable polymer. Biodegradable polymers include, without 
limitation, poly(D.L-lactide-co-glycolide) (PLGA), polylac 
tic acid (PLA), polyglycolic acid (PGA), polycaprolactone 
(PCL), or polyethylene glycol (PEG). Accordingly, the lidded 
particles and particles may be a MEMS or NEMS type device 
that is either silicon-based, polymer-based or both. 
Polymer-based MEMS or NEMS may be formed using 
patternable polymers with a number of different lithography 
methods, such as resists for photolithography (e.g., the 
AZ5209 photoresist), the organosilicon monomer for S-FIL 
(e.g., UV photopolymerizable polymer such as PEGDMA), 
and polymethylmethacrylate (PMMA) that can be used for 
nano-imprint or electronbeam lithography, or Such polymers 
as poly(D.L-lactide-co-glycolide) (PLGA), polylactic acid 
(PLA), polyglycolic acid (PGA), polycaprolactone (PCL), or 
polyethylene glycol (PEG). A wide variety of patternable 
polymers are available, and the particular patternable poly 
mer chosen may depend on the particular application (e.g., 
delivery of a therapeutic agent) or desired properties of the 
lidded particles and particles (e.g., biocompatibility, biode 
gradability, or mechanical robustness). 
Stimuli-Sensitive Hydrogels 
In particular embodiments, the lidded particles and par 
ticles may be comprised of a material that provides for 
stimuli-sensitive release mechanism. This would reduce sys 
temic side effects and target the payload only to diseased 
tissues and specific cellular compartments. Stimuli sensitive 
hydrogels have been developed as Smart drug delivery sys 
tems and biomimetic tissue engineering scaffolds to sense 
environmental changes and induce a structural change or 
degradation (Lutolf et al., Proc. Natl. Acad. Sci. USA 2003, 
100:5413-8; Mann et al., Biomaterials 2001, 22:3045-51: 
Peppas et al., Eur: J. Pharm. Biopharm. 2000, 50:27-46; 
Miyata et al., Adv. Drug Deliv Rev. 2002, 54:79-98; Qiu and 
Park, Adv. Drug Deliv Rev. 2001, 53:321-39: Seliktaret al., J. 
Biomed. Mater. Res. A 2004, 68:704-16. Urechet al., Bioma 
terials 2005, 26:1369-79; Gobin and West, FASEB J. 2002, 
16:751-3. When coupled with a microfabricated reservoir, 
these hydrogels act as a valve, allowing highly controlled 
release of drugs and other molecules (Eddington and Beebe, 
Adv. Drug Deliv Rev. 2004, 56:199-210. 
Stimuli-sensitive hydrogels may be capable of sensing 
environmental change, which may result in a structural 
change. Environmentally sensitive hydrogels have many 
applications in drug delivery. For example, temperature and 
pH sensitive hydrogels can be used for site specific delivery. 
They utilize a change of pH or temperature in the body to 
trigger release of a drug. Alternately, environmentally sensi 
tive hydrogels may respond to a biomolecule (e.g., glucose 
and antigens), light, magnetic fields, and ultrasound. 
Stimuli-sensitive hydrogels may further include an 
enzyme-specific release mechanism. Such a mechanism 
would allow drug release within the endo-lysosomal pathway 
of the target cells, among other things, because enzymatic 
cleavage can break down polymers faster than hydrolysis. 
More particularly, an enzyme degradable membrane fabri 
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cated from photocrosslinked polymers may be used that 
should degrade when exposed to lysosomal enzymes, thus 
allowing, for example, the release a payload into the cell 
milieu, while preventing non-specific release of the payload 
outside target cells. An example of Such an enzyme-specific 
release mechanism is a photocrosslinked, acrylated PEG 
peptide-PEG tri-block copolymer membrane. 
Lids 
As used herein, “lids' of the lidded particles of the present 
invention operate to open the drug delivery devices in Such a 
manner as to be stimuli-responsive. In general, the specific lid 
chosen may depend on the payload of the device. Thus, in 
certain embodiments, the lid may be chosen so as to slow or 
prevent the diffusion of the payload through the lid. In certain 
embodiments, the lid may take the form of a membrane. Such 
as a polymer membrane. Lids may comprise a stimuli-sensi 
tive polymer membrane. Such lids, among other things, 
would allow for protection of any contents or payload that 
may be provided by the particle. For example, such lids may 
be used to delay release of a therapeutic agent until a target 
site is reached. In this way, the lidded container may be 
capable of decreasing the side effects of highly toxic thera 
peutic agents by preventing release of them until the lidded 
particle reaches the cell interior and interacts with the appro 
priate enzymes. 
In specific embodiments, the lids comprise a stimuli-sen 
sitive hydrogel, discussed supra. When coupled with a bio 
compatible particle, these hydrogels can act as a type of valve 
(Low, Sensors Actuators B 2000, 67:49-160), allowing the 
controlled release of a payload, for example, a therapeutic 
agent. 
In certain embodiments, the lids include an enzyme-spe 
cific release mechanism. Such a mechanism would allow 
drug release within the endo-lysosomal pathway of the target 
cells, among other things, because enzymatic cleavage can 
break down polymers faster than hydrolysis. More particu 
larly, an enzyme degradable membrane fabricated from pho 
tocrosslinked polymers may be used that should degrade 
when exposed to lysosomal enzymes, thus allowing, for 
example, the release a payload into the cell milieu, while 
preventing non-specific release of the payload outside target 
cells. An example of such an enzyme-specific release mecha 
nism is a photocrosslinked, acrylated PEG-peptide-PEG tri 
block copolymer membrane. 
One design criterion of the polymer and polymer mem 
brane lids is that they should allow drug release upon enzy 
matic degradation and that there should be minimal diffusion 
of drugs through the membrane before the microcontainers 
have reached their targets. Hence, the crosslinking density of 
the membrane must be such that the pore sizes are smaller 
than the drug molecule sizes. 
Peptide Spacer 
In general, a peptide linking two polymers (termed herein 
a "peptide spacer”) should be enzymatically degradable. Any 
degradable peptide that can be incorporated into a biodegrad 
able polymer can be used. In particular embodiments, the 
peptide Gly-Phe-Leu-Gly (GFLG) is the enzymatically 
degradable peptide component of the polymer membrane lid. 
GFLG is a tetra-peptide sequence that has been widely used in 
tumor targeted polymer-drug conjugates (Peterson et al., Adv. 
Exp. Med. Biol. 2003, 519:101-23; Ulbrich et al., J. Control 
Release 2003, 87: 33-47; Kopecek et al., Eur: J. Pharm. 
Biopharm. 2000, 50:61-81). This peptide spacer is designed 
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to degrade in the lysosome in the presence of lysosomal 
proteases (e.g., cathepsins). Such particle sequences have 
been shown to degrade in rattritosomes and specifically by 
cathepsins C. H. L., and B. 
Peptide spacers have been shown to have different degra 
dation rates based on their size and amino acid sequence 
(Ulbrich et al., 2003, supra; Kopecek et al., 2000, supra; 
Etrych et al., J. Control Release 2001, 73:89-102). It was 
found that the sequence GFLG was especially sensitive to 
Cathepsin B, a protease that has been shown to be over 
expressed in tumor cells. Specifically, Cathepsin B levels in 
tumor cells and tissues of patients with lung cancer, especially 
non-small cell lung cancer (NSCLC), is significantly elevated 
and has been directly related to their prognosis (Krepela et al., 
Neoplasma 1990, 37:61-70; Krepela et al., Int. J. Cancer 
1995, 61:44-53; Krepela et al., Neoplasma 1997, 44:219-39; 
Spiess et al., J. Histochem. Cytochem. 1994, 42:917-29; 
Werleet al., Cancer 2000, 89:2282-91; Jessup, Am. J. Pathol. 
1994, 145:253-62; Heidtmann et al., Clin. Exp. Metastasis 
1997, 15:368-81; Higashiyama et al., J. Clin. Pathol. 1993, 
46:18-22: Erdel et al., J. Histochem. Cytochem. 1990, 38: 
1313–21; Ebert et al., Anticancer Res. 1994, 14: 895-9). 
To facilitate a better understanding of the present inven 
tion, the following examples of specific embodiments are 
given. In no way should the following examples be read to 
limit or define the entire scope of the invention. 
EXAMPLES 
Example 1 
Incorporation of the Peptide GFLGK in a 
Photocrosslinkable PEG Polymer 
The peptide sequence GFLGK (molecular weight (MW) 
527 Daltons, synthesized at ICMB Protein Facility at the 
University of Texas at Austin) was reacted with acrylate 
PEG-N-Hydroxy-succinamide (ACRL-PEG-NHS, MW 
3,400, Nektar Therapeutics, AL). The primary (alpha) amine 
of Glycine (G) and the primary amine of Lysine (K) at either 
end of a peptide molecule reacts with the N-Hydroxy-succi 
namide (NHS) groups of two hetero-bifunctional PEG 
chains, i.e., each peptide molecule crosslinks two PEG mol 
ecules. This creates a 2:1 molar reaction (ACRL-PEG-NHS: 
GFLGK) to form ACRL-PEG-GFLGK-PEG-ACRL (a 
homobifunctional PEG diacrylate). Specifically, the peptide 
was dissolved to a final concentration of 1 mg/mL in 50 mM 
sodium bicarbonate buffer, pH 8.2. Separately, the ACRL 
PEG-NHS was also dissolved in 50 mM sodium bicarbonate 
buffer, pH 8.2. The PEG solution (300 uL) was then added 
one drop at a time into the peptide Solution and reacted at 
room temperature for 2 hours. Next the unconjugated ACRL 
PEG-NHS and free peptides were removed by dialysis (Spec 
trum Spectra/Por 5,000 MWCO dialysis tubing, Fischer Sci 
entific) in deionized water. The solution was dialyzed for 4 
hours at room temperature and then overnight at 4°C. with 
periodic changing of buffer followed by lyophilization of the 
sample. Matrix-assisted laser desorption/ionization time-of 
flight (MALDI-TOF) mass spectrometry (Perspectives Bio 
systems Voyager) was used to Verify conjugation and removal 
of unconjugated material. As shown in FIG. 3 (measured 
before dialyzing through the 500 kD membrane), the pres 
ence of an approximately 7,000 kD peak indicates successful 
conjugation of one peptide to two PEG molecules. The other 
peaks indicate free peptide and free PEGs. 
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Verification of Conjugation 
MALDI-TOF mass spectrometry was used to verify con 
jugation and removal of unconjugated material. This was 
performed by measuring and comparing the molecular 
weight distribution (MWD) of the peptide alone, ACRL 
PEG-NHS (approximate MW 3,400 Daltons), and conju 
gated ACRL-PEG-GFLGK-PEG-ACRL approximate MW 
7,000 Daltons). Dialysis through a 5,000 kD membrane 
yielded a nearly pure population of peptide-linked bifunc 
tional PEG-acrylates suitable for further photocrosslinking. 
Photopolymerization of ACRL-PEG-Peptide-PEG-ACRL 
Polymer 
The photopolymerization process used is similar to that 
described in Hern & Hubell, J. Biomed. Mater. Res. 1998, 
39:266-76, and Bryant et al., Biotechnol. Bioeng. 2004, 
86:747-55, the relevant disclosures of which are incorporated 
herein by reference. The lyophilized ACRY-PEG-GFLGK 
PEG-ACRL was dissolved in PBS in various weight percent 
ages (20%, 30%, 50%, and 100% w/v solutions). The ultra 
violet (UV) photoinitiator, 2-hydroxy-1-4-(hydroxyethoxy) 
phenyl)-2-methyl-1 propanone (I2959, Ciba Geigy), was 
added to the polymer solution at 0.05 or 0.1 wt %. A thin 
square film of the hydrogel was formed by pipetting the 
Solution onto a Teflon coated glass plate. Next, a coverslip 
(No. 1, Fisher) was placed over the solution, and the solution 
was polymerized for varying amounts of time with a UV lamp 
(365 nm, intensity approximately 4 mW/cm, Blak-Ray 
Lamp, Ted Pella Inc.). 
Characterization of PEG-Peptide-PEG Membranes 
One design criterion of the polymer and polymer mem 
brane lids is that they should allow drug release upon enzy 
matic degradation and that there should be minimal diffusion 
of drugs through the membrane before the microcontainers 
have reached their targets. Hence, the crosslinking density of 
the membrane must be such that the pore sizes are smaller 
than the drug molecule sizes. To estimate the pore size of the 
crosslinked peptide-PEG membranes, hydrogel swelling 
studies were performed and the Peppas-Merrill equation 
(Peppas et al., Eur: J. Pharm. Biopharm., 50, 27-46, 2000) 
was used to estimate molecular weight between crosslinks as 
well as the pore-size of the swollen membranes. This pro 
vided a basic idea on what crosslinking densities must be used 
to fabricate membranes for a particular drug size and pro 
vided the theoretical limitation of stimuli-responsive release 
from Such a lid design. 
Degradation of the Polymer Membrane in Presence of Rel 
evant Enzymes 
As a proof of concept, the enzyme-specific release kinetics 
of encapsulated plasmid DNA from a PEG-GFLGK-PEG 
hydrogel (100% w/v) was evaluated in vitro. The experiment 
was performed in duplicate in 0.01M PBS solution (pH 7.4) 
with 0.18% plasmid DNA (w/w of polymer). The DNA 
loaded hydrogels were placed in 2 mL tubes in PBS buffer (1 
mL), and were placed on a shaker in an incubator at 37°C. for 
the duration of the study. At various time intervals (2 hrs, 4 
hrs, 6 hrs, 8 hrs, 12 hrs, 24 hrs, 48 hrs, 72 hrs), buffer samples 
were collected. At each time point 100 uL of buffer was 
removed and 100LL of fresh buffer was replaced. At the 72 hr 
time point, the entire PBS buffer solution was removed from 
the samples. Then a 1 mL solution of Cathepsin B (10 U/mL 
in PBS pH 5) was added to each sample. The samples were 
returned to the incubator and at various time intervals buffer 
samples were collected. Each time 100 uL of enzyme solution 
was removed, and 100 uL of fresh enzyme solution was 
replaced. The amount of plasmid DNA released into buffer 
was measured for each time point using the NanoDrop. As 
expected, when Cathepsin B was introduced, DNA was rap 
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idly released, demonstrating that specific enzyme-induced 
burst release does occur (data not shown). 
Another assay for the degradation of the polymer mem 
brane utilizes rhodamine alone or various molecular weights 
of dextran-rhodamine conjugates (MW 10,000, 40,000, and 
70,000 Daltons). Rhodamine or dextran-rhodamine mimics a 
Small molecule drug or peptide?protein drugs and permits 
evaluating their diffusion through polymer membranes of 
various crosslink density (e.g., 10%, 50%, 75% and 100% 
w/w PEG-peptide-PEG polymers). To determine the rate of 
release of the model drug due to enzymatic degradation, 
degradation/release assays are performed on the polymer 
membranes with encapsulated model drugs (rhodamine or 
dextran rhodamine). Either rhodamine alone or dextran 
rhodamine conjugates (Molecular Probes Inc., Eugene, 
Oreg.) is added to the polymer precursor prior to photopoly 
merization. Thin layer membranes are fabricated by spin 
coating the polymer Solutions and photopolymerizing using a 
UV lamp. These rhodamine-containing polymer membranes 
are incubated at 37° C. either in PBS alone or in PBS con 
taining various concentrations of Cathepsin B (e.g., 0.5 to 1 
uM). These concentrations have been previously shown to be 
optimal for degradation of the GFLG peptide. Enzymatic 
degradations with Cathepsin Bare performed in a series of pH 
conditions (e.g., pH 5, 5.5, 6, 6.5, and 7. Sodium phosphate 
buffers) to evaluate the effects of environmental pH on 
enzyme activity and mimic the endolysosomal pH conditions. 
At various time points, rhodamine release from various mem 
brane samples (e.g., 10-100% w/w polymer membranes) is 
evaluated using a fluorometer (570 nm excitation, 590-600 
nm emission). Membrane crosslinking densities that allow 
for minimal drug release in the absence of any enzymes but 
allow immediate release in the presence of the enzyme are 
used for further studies. 
Example 2 
Fabrication Using Nanoimprint Lithography 
Technique 
We employed the S-FIL nanoprint process (discussed 
Supra) to imprint nanopatterns on polymers. In addition to the 
S-FIL method, we employed a thermal nanoprint process to 
imprint nanopatterns on a variety of other polymers including 
PMMA, BCB, hydrogensilsesquioxane (HSQ) and the elec 
tron beam resist ZEP 520A (FIG. 1). In this thermal nanoim 
print process, the polymer film was heated to a temperature 
slightly higher than the glass transition temperature. The 
imprint template was treated with a release layer (such as 
Hexadecanethiol or Octanethiol for a GaAs imprint template) 
to facilitate the separation of the template from the polymer 
layer upon cooling. Because the polymer does not need to be 
photolinkable, the thermal nanoimprint process can be used 
to pattern a wide variety of polymers. 
Example 3 
Fabrication of Templates for Thermal 
Nanoimprinting of Drug Delivery Lidded Particles 
FIG. 4 shows a schematic for the nanoimprint fabrication 
process of lidded particles as shown in FIG. 5, infra. Two 
reusable quartz templates for nanoimprinting are fabricated 
as described. 
To make an example particle for use as a monodisperse 
drug carrier, we fabricated both silicon and quartz imprint 
templates using electron-beam lithography (EBL) combined 
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with reactive ion etching (RIE) following an established pro 
cedure (Bailey et al., 2002, supra). Four inch p-type <100> 
silicon test wafers were pre-cleaned with Pirhana. The wafers 
were then pre-baked (180°C.,30s), spin coated with ZEP520 
(3000 rpm for 60 sec.), and finally soft-baked (180° C., 30 
sec.). Next the wafers were patterned using e-beam lithogra 
phy (JEOL JBX-6000FS/E) with the following process 
parameters: EOS mode 7, 50 kV, 100 p.A, exposure level/ 
dose: 20 to -20. Between each step the wafers were devel 
oped with ZED n50 (15-30 sec.), rinsed with isopropyl alco 
hol (IPA) (30 sec.), and dry etched using a Plasma Therm 790 
Series Reactive ion etcher (gases: HBr, Cl, He) to etch the 
silicon surface below. FIG. 5 shows SEM images of device 
features fabricated with the EBL. REI and ThNIL techniques. 
FIGS.5A-5D show a silicon wafer with an open box (lid-free 
particle) template for Subsequent nanoimprinting. Precise 
template structures with sub-200 nm features can be created 
using this process. FIGS. 5A and 5B are SEM images of 
E-beam templates prior to the RIE step;5C and 5D shows the 
template features following RIE. 
Depending on the polymeric material used, both the ther 
mal nanoimprint process and S-FIL process can be to make 
drug delivery particles. The thermal nanoimprint process was 
performed on a polymethyl-methacrylate (PMMA) layer 
(300 nm thick, 950 kD in anisole) spun on a 4-inch silicon 
substrate (FIG. 5E, 5F). Prior to imprinting, the imprint tem 
plate was treated with a self-assembled monolayer (SAM) of 
Dow-corning release agent 20 to facilitate the separation of 
the template from the PMMA layer. The PMMA film was 
then heated above its glass transition temperature (105° C.) 
using a heater chuck under the wafer and the imprint template 
was pressed into the PMMA for 10 minutes using a micro 
manipulator with a built-in force sensor. Experiments were 
conducted to determine the appropriate pressure for an 
imprint depth of about 200 nm. The template was then lifted 
using the micromanipulator and separated from the wafer 
after the wafer temperature had reduced to 60° C. Finally, 
residual PMMA was removed using timed oxygen plasma 
cleaning and the PMMA nano-devices were released in water. 
These PMMA nano-boxes were released in water. As shown 
in the SEM images (FIG. 5E, 5F), highly precise, uniformly 
distributed, 200-nm and 400-nm lidded particles were fabri 
cated using this process. 
We have also employed the S-FILTM method using an 
IMPRIO 100 S-FILTM tool to directly imprint peptide-func 
tionalized PEG membranes onto a silicon substrate. The step 
and flash process allowed for high-throughput, wafer-scale 
patterning of the photolinkable polymer into drug delivery 
vehicles. To show that the peptide functionalized polymer 
membranes could be photopolymerized and imprinted using 
S-FILTM, we imprinted the polymer using a standard template 
with nano-line array patterns. We imprinted 50-nm wide 
nano-lines in PEG. The minimum line width that can be 
obtained by S-FILTM process is smaller than 20 nm (data not 
shown). 
Example 4 
Fabrication of Lidded Particles with 
Stimuli-Responsive Lids Nanoimprinting of 
Drug-Containing Lidded Particles 
A schematic for the nanoimprint fabrication process of 
lidded particles is shown in FIG. 4. Two reusable quartz 
templates for nanoimprinting are fabricated as described in 
Example 3. 
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The first imprint process was performed on a PMMA layer 
(100 nm thick, 120 Kd molecular weight) spun on a 4 inch 
silicon Substrate using the thermal nanoimprint setup (FIG. 
4A-4C). Prior to imprinting, the imprint template was treated 
with a self-assembled monolayer (SAM) of Dow-Corning 
release agent 20, and the release layer facilitated the separa 
tion of the template from the PMMA layer. Residual PMMA 
(FIG. 4D) was removed using timed oxygen plasma cleaning. 
Atherapeutic agent (e.g., drug) solution was then spin-coated 
on the wafer (FIG.4E). After the solution dried, the wafer was 
washed briefly in DI water to remove excess drug from the 
SiO surface, the side walls and the top of the PMMA lid-free 
particles (FIG. 4F). 
To form the lid, a 100-nm thick PEG-peptide-PEG polymer 
(e.g., PEG-GFLK-PEG or PEG-GFLGK-PEG) layer was 
then coated on the wafer, and the S-FILTM technique was used 
to pattern the second imprint. The second imprint template 
loaded in the S-FILTM tool was pressed into the hydrogel after 
alignment between the alignment marks on the template and 
those left in the PMMA layer after the first imprint step (FIG. 
4G). The UV-crosslinkable polymer was then exposed to UV 
light and cured (FIG. 4H). The imprint force and time was 
optimized, and was in the range of 2-3 N and 1-2 minute, 
respectively. After the template was lifted by the S-FILTM tool 
and separated from the wafer, short oxygen plasma cleaning 
was used to clean the residual polymer and separate the nano 
drug containers (FIG. 4I). The size of the lidded particle was 
limited by the alignment accuracy between the first and sec 
ond imprinting steps. Because the S-FILTM imprint equip 
ment can achieve Sub-100 nm alignment accuracy with a 
minimum line width smaller than 20 nm, lidded particles of 
sizes 800, 500, 300, and 200 nm could be successfully fabri 
cated. 
The lidded particles are also formed using alternatives to 
nanoimprint lithography, Such as using a combination of UV 
and nanoimprint lithography, as described in the following 
references, the relevant disclosure of each is incorporated 
herein by reference: Plachetka et al., Microelectr. Eng. 2004, 
71:277-82; Forsen et al., Microelectr. Eng. 2002, 73-74:491 
95; and Cheng and Guo, Microelectr. Eng. 2004, 71:288-93. 
Release and Isolation of Lidded Particles 
The fabricated lidded particles are released (as particles) 
from the wafer in a manner similar to that described by Desai 
and colleagues for microdevices; however, we modify that 
procedure to avoid high temperature or harsh chemical reac 
tions that could potentially damage the PEG-peptide lidor the 
drug inside the particle. The following three methods are used 
evaluated to release the containers: (i) the 100 nm layer of 
SiO, underneath the photoresist is wet etched with a HF 
solution diluted in deionized (DI) water (1 part HF: 100 parts 
DI water) for an experimentally determined amount of time: 
(ii) use of a diluted base solution (6 M KOH, 5 min, 65°C.) to 
undercut the containers (Tao et al., J. Control Release 88. 
215-28, 2003a; Tao et al., J. Biomed. Mater. Res. A 67, 369 
75, 2003b); (iii) we have also found that the nano-imprinted 
polymer particles in FIG. 5 can be released from the wafer 
surface after the wafer was soaked in DI water for a long time 
because of the poor adhesion between the polymer and the 
SiO surface. The obtained solution will be vacuum filtered 
through a Whatman membrane filter (0.1L pore size. What 
man Inc., NJ) to isolate the lidded particles. The collected 
devices are washed and resuspended in DI water and subse 
quently vacuum filtered to isolate clean lidded particles. 
Loading levels of the protein or DNA drug are evaluated using 
HPLC following complete dissolution of the membrane in the 
presence of Cathepsin B. 
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Evaluation of Drug Release from Lidded Particles 
To determine the enzyme-triggered drug release from the 
nanofabricated lidded particles, in vitro release studies are 
carried out in the presence or absence of Cathepsin B and an 
irrelevant enzyme (e.g., lysozyme) as controls. Briefly, par 
ticles loaded with the model drugs (at 1 mg/ml BSA or DNA 
concentration as determined by drug loading measurements) 
are incubated in cell culture medium at 37° C. Various 
amounts of Cathepsin B (0.5 to 1 uM) are added to the wells 
and similar concentrations of lysozyme (as irrelevant enzyme 
control) are added to determine specificity. At various inter 
vals (e.g., 15 min, 30 min, 1 hr, 2 hrs, 6 hrs and 24 hrs), the 
lidded particles are separated by centrifugation and 200 ul of 
the supernatant is removed and replaced by fresh buffer. The 
collected buffer samples are subjected to HPLC measure 
ments as detailed above to determine the concentration of the 
released drugs over time. 
The above method of the present invention can also be 
scaled to make particles having a size of up to about 1000 
microns. 
Example 5 
Fabrication of Nanoimprinted Particles 
Fabrication of Thermally Imprinted Nanoparticles 
Depending on the polymeric material used, both the ther 
mal nanoimprint process and S-FILTM process can be used to 
make drug delivery particles. In a particular embodiment, the 
thermal nanoimprint process is performed on a polymethyl 
methacrylate (PMMA) layer (300 nm thick, 950 kD in ani 
sole) spun on a 4-inch silicon substrate. Prior to imprinting, 
the imprint template is treated with a self-assembled mono 
layer (SAM) of Dow-Corning release agent 20 to facilitate the 
separation of the template from the PMMA layer. The PMMA 
film is then heated above its glass transition temperature 
(105°C.) using aheater chuck under the wafer and the imprint 
template is pressed into the PMMA for 10 minutes using a 
micromanipulator with a built-in force sensor. Experiments 
are conducted to determine the appropriate pressure for an 
imprint depth of about 200 nm. The template is then lifted 
using the micromanipulator and separated from the wafer 
after the wafer temperature had reduced to 60° C. Finally, 
residual PMMA is removed using timed oxygen plasma 
cleaning and the PMMA nano-devices are released in water. 
In an alternate embodiment, the thermal nanoimprint pro 
cess is performed on poly(lactic-co-glycolic acid) (PLGA) 
polymer layer (300 nm thick) spun on a 4-inch silicon sub 
strate. PLGA is an FDA approved, biocompatible and biode 
gradable polymer widely used for drug delivery, tissue engi 
neering, Surgical Sutures. Although particles fabricated using 
PLGA releases drug purely by diffusion and degradation and 
is not disease-responsive, the process developed here allows 
for a novel fabrication method that provides highly monodis 
perse particles of precise size and shape along with a high 
drug loading efficiency. For spin coating, the polymer is first 
dissolved in dichloromethane and spun on the silicon wafer. 
The layer thickness is optimized by varying the spinning 
speed and the polymer concentration (i.e. viscosity). 
FIG. 6 shows a schematic diagram of a procedure for 
nanoparticle fabrication using thermal nanoimprinting. Prior 
to imprinting, the imprint template is treated with a self 
assembled monolayer (SAM) of Dow-corning release agent 
20 to facilitate the separation of the template from the poly 
mer layer. Next, the PLGA layer is spun onto the wafer and 
the polymeric film is heated above the glass transition tem 
perature (50° C. for PLGA) using a heater chuck under the 
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wafer. Subsequently, the imprint template is pressed into the 
PMMA for 10 min using a micromanipulator with a built-in 
force sensor. The template is then lifted using the microma 
nipulator and separated from the wafer after the wafer tem 
perature had reduced to 40° C. Finally, residual PLGA is 
removed using timed oxygen plasma cleaning. 
Fabrication of Nanoimprint Templates 
To make a nanoparticle for use as a monodisperse drug 
carrier, a reusable nano-imprint template with various shapes 
was created using e-beam lithography and reactive ion etch 
ing. Four inch p-type <100> silicon test wafers were pre 
cleaned with Pirhana. The wafers were then pre-baked (180° 
C.,30s), spin coated with ZEP520 (3000rpm for 60 sec.), and 
finally soft-baked (180° C., 30 sec.). Next the wafers were 
patterned using e-beam lithography (JEOL JBX-6000FS/E) 
with the following process parameters: EOS mode 7, 50 kV. 
100 p.A, exposure level/dose: 20 to -20. Between each step 
the wafers were developed with ZED n50 (15-30 sec.), rinsed 
with IPA (30 sec.), and dry etched using a Plasma Therm 790 
Series Reactive ion etcher (gases: HBr, Cl, He) to etch the 
silicon surface below. 
Fabrication of Disease-Responsive Nanoparticles Using 
S-FILTM 
In a particular embodiment of the present invention, we 
have employed the S-FILTM method using an IMPRIO100 
S-FIL tool to directly imprint peptide-functionalized PEG 
membranes onto a silicon Substrate. The step and flash pro 
cess allows for high-throughput, wafer-scale patterning of the 
photolinkable polymer into drug delivery vehicles. To show 
that the peptide functionalized polymer membranes could be 
photopolymerized and imprinted using S-FIL, we imprinted 
the polymer using a standard template with nano-line array 
patterns. The step and flash process allows for high-through 
put, wafer-scale patterning of the photo crosslinkable poly 
mer into Solid, drug loaded nano-carriers. In this process, the 
quartz template was treated with a release layer (Relmat) and 
loaded on the IMPRIO 100. Five microliters of the enzyme 
responsive polymer was then dropped onto the wafer. Subse 
quently the template was pressed onto the wafer and then 
exposed to UV light and cured for 90 sec. The imprint force 
and time is optimized, and is in the range of 2-3 N and 1-2 
minute, respectively. The template is then lifted by the S-FIL 
tool and separated from the wafer. A short, oxygen plasma 
cleaning is used to clean the residual polymerand separate the 
particles. The nanoimprinted particles are released similar to 
the process described supra using either diluted HF, mild 
basic solution, or DI water. FIG. 8 shows images of 100-200 
nm particles fabricated according to the method of the inven 
tion. Particles on the order of 400 nm were also fabricated 
according to the method of the invention (data not shown). 
Atomic force microscopy was used to determine the height of 
the particles, which were determined to be approximately 200 
nm high. 
The number of lidded particles and particles that can be 
obtained from a single silicon wafer can be calculated. Using 
a 4" wafer, approximately 2.78x10950 umx50 um containers 
or particles can be fabricated if using a minimum spacing of 
4 um. For 300 nmx300 nm nanocontainers or particles, 
approximately 2.25x1010 can be fabricated if using a mini 
mum spacing of 300 nm. These values are similar to that 
obtained from approximate 10 to 100 mg of polymer micro 
or nanocontainers or micro- or nanoparticles using emulsion 
processes. Therefore, a single wafer processing yields con 
tainer or particle numbers equivalent to a medium scale par 
ticle synthesis using conventional bottom methods. Details of 
the calculations are provided in FIG. 9. 
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While the present disclosure is susceptible to various modi 
fications and alternative forms, specific example embodi 
ments have been shown in the figures and are herein described 
in more detail. It should be understood, however, that the 
description of specific example embodiments is not intended 
to limit the invention to the particular forms disclosed, but on 
the contrary, this disclosure is to cover all modifications and 
equivalents as defined by the appended claims. 
All patents, patent applications, publications, products 
descriptions, and protocols, and references cited herein are 
incorporated by reference for all purposes, and specifically 
for a referenced method or procedure. 
We claim: 
1. A method for making a plurality of monodisperse, solid 
particles comprising: 
placing, on a silicon substrate, a patternable biodegradable 
polymer comprising a therapeutic agent, an imaging 
contrast agent, or both incorporated into a polymer 
matrix of the polymer; 
placing a release layer on an imprint template; 
imprinting the polymer by pressing the release layer and 
imprint template into the polymer, thereby forming a 
plurality of monodisperse, solid particles between 50 
nm and 1000 nm in size corresponding to a plurality of 
particle-shaped portions of the imprint template and 
containing the therapeutic agent, an imaging contrast 
agent, or both, and also forming a residual polymer layer 
on the silicon substrate; 
removing the imprint template: 
Oxygen plasma cleaning the plurality particles and residual 
polymer layer on the silicon substrate to remove the 
residual polymer layer; and 
releasing the plurality of particles. 
2. The method of claim 1, further comprising forming the 
imprint template using e-beam lithography, reactive ion etch 
ing, or both. 
3. The method of claim 1, wherein the polymer comprises 
a compound comprising, polyethylene glycol functionalized 
peptide, biodegradable photocrosslinkable polymers, biode 
gradable acrylate functionalized polymers, poly(D.L-lactide 
co-glycolide), polylactic acid, polyglycolic acid, polycapro 
lactone, polyethylene glycol, or a combination thereof. 
4. The method of claim 1, wherein imprinting comprises 
applying pressure and heat to the imprint template. 
5. The method of claim 1, wherein the imaging contrast 
agent comprises an MRI imaging agent. 
6. The method of claim 1, wherein the imaging contrast 
agent comprises a quantum dot or a gold nanoparticle. 
7. The method of claim 1, wherein releasing the plurality of 
particles comprises releasing with water. 
8. The method of claim 1, wherein placing the patternable 
biodegradable polymer on the silicon substrate comprises 
spin-coating. 
9. The method of claim 1, wherein the imprint template is 
pressed into the polymer and removed from the polymer with 
a micromanipulator. 
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10. The method of claim 1, wherein the imprint has a depth 
of 200 nm. 
11. The method of claim 1, wherein the monodisperse, 
solid particles are from 50 nm to 300 nm in size. 
12. A method for making a plurality of monodisperse, solid 
particles comprising: 
placing, on a silicon substrate, a patternable biodegradable 
polymer comprising a therapeutic agent, an imaging 
contrast agent, or both incorporated into a polymer 
matrix of the polymer; 
placing a release layer on an imprint template: 
imprinting the polymer by pressing the release layer and 
imprint template into the polymer, thereby forming a 
plurality of monodisperse, solid particles between 50 
nm and 1000 nm in size corresponding to a plurality of 
particle-shaped portion of the imprint template and con 
taining the therapeutic agent, an imaging contrast agent, 
or both, and also forming a residual polymer layer on the 
silicon substrate; 
removing the imprint template: 
oxygen plasma cleaning the plurality particles and residual 
polymer layer on the silicon substrate to remove the 
residual polymer layer; and 
releasing the plurality of particles, 
wherein the biodegradable polymer is sensitive to a bio 
molecule, light, a magnetic field, ultrasound, pH or tem 
perature, resulting in release the therapeutic agent. 
13. The method of claim 12, further comprising forming 
the imprint template using e-beam lithography, reactive ion 
etching, or both. 
14. The method of claim 12, wherein the polymer com 
prises a compound comprising, polyethylene glycol function 
alized peptide, biodegradable photocrosslinkable polymers, 
biodegradable acrylate functionalized polymers, poly(D.L- 
lactide-co-glycolide), polylactic acid, polyglycolic acid, 
polycaprolactone, polyethylene glycol, or a combination 
thereof. 
15. The method of claim 12, wherein imprinting comprises 
applying pressure and heat to the imprint template. 
16. The method of claim 12, wherein the imaging contrast 
agent comprises an MRI imaging agent. 
17. The method of claim 12, wherein the imaging contrast 
agent comprises a quantum dot or a gold nanoparticle. 
18. The method of claim 12, wherein releasing the plurality 
of particles comprises releasing with water. 
19. The method of claim 12, wherein placing the pattern 
able biodegradable polymer on the silicon substrate com 
prises spin-coating. 
20. The method of claim 12, wherein the imprint template 
is pressed into the polymer and removed from the polymer 
with a micromanipulator. 
21. The method of claim 12, wherein the imprint has a 
depth of 200 nm. 
22. The method of claim 12, wherein the monodisperse, 
solid particles are from 50 nm to 300 nm in size. 
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